Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Celgene Shares Good News On Ozanimod, Quietly Dumps Pricey GED-0301

May 06 2018

• By Mandy Jackson

Business decline

Related Content

Celgene's Partnered Pipeline Delivers Successes And Setbacks

Nov 21 2017

Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends

Oct 20 2017

Pharma Q1 Results Preview: Merck & Co, Pfizer, Gilead, Novo Nordisk, Teva, Celgene

Apr 27 2018

Celgene's Terrie Curran On Building, Broadening The I&I Franchise

Apr 04 2018

Deal Watch: Roivant Adds Ligand's Glucose Receptor Antagonist To Metavant Pipeline

Mar 07 2018

1Q EARNINGS: Celgene boosts sales, bets big on Crohn's drug

Apr 25 2014

Celgene diversifies with $7.2bn Receptos buy

Jul 15 2015

Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy

Jan 23 2018

Celgene's IBD Franchise Boosted by Otezla Ulcerative Colitis Success

Feb 16 2018

More Bad News: Celgene Reveals Refuse-To-File Letter For Ozanimod In MS

Feb 28 2018

Related Companies

Bristol Myers Squibb Company

Vividion Therapeutics, Inc.

Receptos, Inc.

Bristol Myers Squibb Company

Nogra Pharma Ltd.

Additional Topics

Sales & Earnings Business Strategies Companies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window